Quay adds Dedicated Ph III Packing and Distribution Capacity

By Gareth Macdonald

- Last updated on GMT

Quay adds Dedicated Ph III Packing and Distribution Capacity
Quay adds Dedicated Ph III Packing and Distribution Capacity

Related tags: Pharmacology

Quay Pharma has added dedicated packaging distribution capacity to support Phase III trials in response to customer demand.

The Welsh contract services firm has invested £100,000 to add dedicated packing capacity for late stage clinical trials at its facility Deeside​ and also hired extra staff. The new capacity has been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA).

Quay said the new area gives it the flexibility to respond to client requirements for both bulk delivery of product and to meet increasing demands for just in time deliveries to support randomised and blinded studies.

CEO Maireadh Pedersen expanded on this, telling Outsourcing-pharma.com that: “This investment was made in response to increasing support for our current customers…They have worked with us through formulation development.

We were able to do both [packing and distribution] before but the scale of what we could do was limited to Phase I/II. We can now support quite complex and larger Phase III trials."

Customer driven

Pedersen said the main drive for the investment was a request from an unnamed French pharmaceutical customer developing drugs for neurodegenerative disorders, whose lead candidate is set to enter larger, pan European studies.

But while this French client may have been the key prompt for the investment, Quay has also seen an increase in demand for late stage packaging and distribution services from other customers with drugs in development.

As more of our clients are getting positive trial results and progressing through the clinical phases we are able to support them for longer. We work on many oncology products and these trials can require support for many years.

For example, one product for which we are one of the clinical distributors has been supported by Quay for five years. For this product we are still supplying product to named patients all over the world with the product being requested, shipped and received by the patient/clinic within 24 hours of request.”

Related news

Related products

show more

A Winning End-to-End Solution for Oncology Studies

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars